Cytokinetics' aficamten Phase 3 success triggers $75M milestone for Royalty Pharma

Royalty Pharma plc

Cytokinetics announced positive Phase 3 SEQUOIA-HCM results for aficamten in symptomatic obstructive HCM.
Royalty Pharma holds a 4.5% global royalty on aficamten (3.5% on sales >$1B) as per Jan 2022 agreement.
Royalty Pharma provided $50M commercial launch capital; Cytokinetics can now draw $75M milestone.
Additional $100M milestone payable upon FDA acceptance of aficamten NDA.
Full results to be presented at upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.